Grace Therapeutics, Inc.
Income Statement
| Line Item | Dec 2021 | Dec 2020 |
|---|---|---|
| Revenue | $0 | $81.0K |
| Cost of Revenue | $0 | $36.0K |
| Gross Profit | $0 | $45.0K |
| Gross Margin | — | 55.6% |
| Operating Expenses | ||
| Research & Development | $2.2M | $678.0K |
| SG&A Expense | $1.8M | $1.1M |
| Operating Income | $-4.5M | $-2.0M |
| Operating Margin | — | -2,424.7% |
| Interest Expense | — | — |
| Pretax Income | $-3.8M | — |
| Income Tax Expense | $0 | — |
| Net Income | $-3.8M | $-3.2M |
| Net Margin | — | -3,975.3% |
| EPS (Basic) | $-0.09 | $-0.26 |
| EPS (Diluted) | $-0.09 | $-0.26 |
| Shares Outstanding (Basic) | 44.3M | — |
| Shares Outstanding (Diluted) | 44.3M | — |
| Dividends Per Share | — | — |